In the market for Total Joint Replacement, companies continue to innovate with assistive technologies and new implants and instruments to advance clinical outcomes and increase efficiency of care. From new hip products optimized for the direct anterior approach to cementless knee solutions, companies are focusing on technologies that provide optimal outcomes whether surgeries are performed in a hospital, hospital outpatient or ASC setting. The following is a sample of SmartTRAK's recent Total Joints news and developments from around the world, compiled, curated and posted in real time by the expert analysts at SmartTRAK.

We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. If you'd like to receive these expert insights daily, Contact Us to learn more. Our users think it's the perfect way to start their day.

• JNJ/DePuy Synthes*
  

  JNJ/DePuy Synthes did not discuss its new EMPHASYS hip implants during its Q322 earnings call. However, SmartTRAK would not be surprised to see the Company introduce the system at AAHKS 2022 with the EMPHASYS Cup* recently receiving 510(k) clearance to round out the platform.

• Exactech*

  Exactech announced the successful first surgeries and limited launch of the Novel Total Hip Arthroplasty System with the Spartan Stem* and Logical Cup* with full commercial US launch planned for H123. Exactech is a distributor of the implants supplied by Signature Orthopaedics*.

Despite stronger headwinds from slowing elective procedures, supply chain challenges and unfavorable foreign exchange rates, most total joint companies saw positive growth in Q222.

The WW Total Joints Market grew in Q222 despite slowing sequential growth compared to Q122’s growth. A slowdown in elective procedures late in the quarter along with continued supply chain challenges and the effect of foreign exchange rates resulted in stronger headwinds. SmartTRAK notes that several companies reported the carryover of these headwinds into Q3 that could dampen market recovery through year-end.

Among the many topics covered in detail in our comprehensive Q222 Total Joints Market Recap* are:

Procedure volume recovery is not the only trend on SmartTRAK’s radar

Procedure volume recovery continues to be a trend on everyone’s radar from industry execs to healthcare providers. In Q122, the Knee Replacement Market in the US seemed to experience a much stronger recovery than Hips based on YoY growth rates, according to SmartTRAK Financial Dashboard. However, Knees faced a much easier YoY comp as more knee procedures were postponed in Q121 compared to hips due to their more elective nature. Putting this into perspective, US Hip Market growth along with Knees reinforced the feeling that 2022 procedures will be closer to “normal” as the Total Joints Market recovers from the downsizing caused by COVID.  And, as the industry’s bandwidth for focusing on the pandemic decreases, the emphasis on other trends grows.

Among the many topics covered in detail in our comprehensive Q122 Total Joints Market Recap* are:

From economics to the ASC shift, SmartTRAK looks at the trends affecting the Total Joints Market

The start of the new year did not play out as so many of us had hoped. Heading into 2022, the next COVID surge reared its ugly head with the Omicron variant storming through countries around the globe. Healthcare facilities once again postponed elective procedures due to capacity issues and/or staff or patients being diagnosed with COVID. Overall inflation rose to a level that hasn’t been seen since the early 1980s. Looking ahead, is there a silver lining in this dark cloud? SmartTRAK believes the forecast is not all doom and gloom. Let’s look at some of the trends affecting the climate of the Total Joints market.

(Continue reading to find out how to receive FREE SmartTRAK DAILY UPDATES)